Pelage Pharmaceutical raised $14M in a Series A-1 funding led by GV to accelerate its Phase 2 clinical program for hair loss treatments.
Pelage Pharmaceutical raised $14M in a Series A-1 funding led by GV to accelerate its Phase 2 clinical program for hair loss treatments.
08/13/24, 1:53 PM
Location
los angelesMoney raised
$14 million
Industry
biotechnology
healthcare
Investors
Gv
Pelage Pharmaceutical, a clinical-stage regenerative medicine company, raised $14M in Series A-1 funding. The funds will be used to speed up its Phase 2 clinical program for treating hair loss, specifically targeting androgenetic alopecia and chemotherapy-induced alopecia.
Company Info
Location
los angeles, california, united states
Additional Info
At Pelage Pharmaceuticals, our goal is to deliver a scientifically based, clinically tested treatment for both men and women battling the emotional pain or social stigma of hair loss.
Based on the breakthrough innovation by Pelage Pharmaceuticals co-founders, we stimulate hair growth by targeting the metabolism of hair follicle stem cells in most forms of alopecia.